Literature DB >> 1645382

Activity of azithromycin against cryptosporidia in immunosuppressed rats.

J E Rehg1.   

Abstract

Dexamethasone-immunosuppressed rats infected with Cryptosporidium parvum were used to assess the macrolides azithromycin and spiramycin for anticryptosporidial activity. Azithromycin consistently prevented ileal infection, while spiramycin was ineffective. The anticryptosporidial activity of azithromycin was dose-related, 200 mg/kg/day being the minimum dose that prevented infection. Therapeutically, azithromycin eliminated an established overt infection of the small intestine in immunosuppressed rats, but the infection recurred after azithromycin treatment was stopped. These findings suggest that azithromycin is a potentially useful anticryptosporidial agent and that long-term continuous administration may be necessary to treat cryptosporidiosis in the immunocompromised host.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645382     DOI: 10.1093/infdis/163.6.1293

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

2.  Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin.

Authors:  D Dionisio; A Orsi; G Sterrantino; M Meli; S Di Lollo; L Ibba Manneschi; M Trotta; M Pozzi; L Sani; F Leoncini
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

3.  Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients.

Authors:  C Dupont; M E Bougnoux; L Turner; E Rouveix; M Dorra
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis.

Authors:  J W Benbow; E L Bernberg; A Korda; J R Mead
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.

Authors:  M W Riggs; V A Cama; H L Leary; C R Sterling
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; C Carbon; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.

Authors:  Momar Ndao; Milli Nath-Chowdhury; Mohammed Sajid; Victoria Marcus; Susan T Mashiyama; Judy Sakanari; Eric Chow; Zachary Mackey; Kirkwood M Land; Matthew P Jacobson; Chakrapani Kalyanaraman; James H McKerrow; Michael J Arrowood; Conor R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.

Authors:  Sangun Lee; Melanie Harwood; Don Girouard; Marvin J Meyers; Mary A Campbell; Gillian Beamer; Saul Tzipori
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.